Merck Numelvi (atinvicitinib tablets) for Dogs

Merck Numelvi (atinvicitinib tablets) is an oral prescription medication used to control pruritus associated with allergic dermatitis in dogs 6 months of age and older. This second-generation JAK inhibitor is designed for targeted itch control, helping improve comfort and quality of life for dogs with allergic skin conditions.

• Targeted itch control: Second-generation JAK inhibitor developed specifically to address allergic dermatitis–related itch in dogs.
• JAK1-selective action: Highly selective for JAK1, a key driver of itch and inflammation pathways.
• Fast onset of relief: Onset of itch relief typically observed within 2 to 4 hours.
• Proven clinical results: Demonstrated significant improvement in itch within one week in clinical studies.
• Simple daily routine: Once-daily oral dosing for dogs 6 months of age and older weighing at least 2 kg.

Numelvi targets the underlying pathways of itch and inflammation associated with allergic dermatitis. By selectively inhibiting JAK1, it helps interrupt the signals that trigger itching, allowing dogs to experience relief while supporting healthier, more comfortable skin.

• Use: Control of pruritus associated with allergic dermatitis in dogs.
• Species: Dogs 6 months of age and older.
• Minimum weight: For dogs weighing at least 2 kg.